Sarah Ollis

Biochemistry, Genetics and Molecular BiologyEconomics, Econometrics and FinanceMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments”.

Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments

Orphanet Journal of Rare Diseases(2024)10.1186/s13023-024-03277-9

N/A

0.326DataRank · unranked

5 citations

Ahmet Özen, Sarah Ollis, Hagit Baris Feldman, Andrew Yaworsky, Paolo Medrano +9 more

The patient experience of CHAPLE disease: results from interviews conducted as part of a clinical trial for an ultra-rare condition

Orphanet Journal of Rare Diseases(2025)10.1186/s13023-024-03436-y

N/A

0.179DataRank · unranked

2 citations

Ahmet Özen, Sarah Ollis, Hagit Baris Feldman, Andrew Yaworsky, Paolo Medrano +11 more